Why Most FQHCs Are Leaving 340B Revenue on the Table (and What Their Analytics Should Be Showing Them)

The 340B Drug Pricing Program is one of the most significant revenue streams inside FQHCs — and one of the most under-optimized. Most FQHCs capture 50-70% of the 340B revenue available to them. The gap is rarely in the program structure; it's in the analytics that connect prescriptions to eligible patient encounters.

Where 340B revenue leaks

Four common leak points:

1. Eligible scripts written but filled outside the contract pharmacy network. The prescription was eligible; the patient filled it elsewhere. Contract pharmacy outreach and patient education close this gap.
2. Specialist referral scripts. When an FQHC referral leads to a specialist prescription, the script may be 340B-eligible if the specialist visit was within the FQHC's scope. Many programs miss these because the referral chain isn't tracked in the 340B system.
3. Encounter-to-prescription matching errors. The 340B audit logic requires a documented qualifying encounter within the look-back window. Encounters that didn't code correctly or weren't completed in the EHR don't count.
4. Duplicate-discount conflicts. 340B rules prohibit duplicate discounts (340B + Medicaid rebate). Programs that don't carve out Medicaid script claims accurately leave 340B revenue and trigger compliance findings.

The four analytics views that recover the revenue

1. Encounter-to-script linkage report. For each filled prescription, was there a qualifying encounter? Patients with scripts filled but no documented qualifying visit are either compliance risks or missed revenue, depending on the cause.
2. Contract pharmacy fill rate by patient. What percentage of eligible scripts are being filled in the contract pharmacy network vs leaking? Patients with low fill rates are outreach candidates.
3. Referral script tracking. Specialist referrals that resulted in scripts. The analytics question: how many of these are eligible under the FQHC scope and being captured?
4. Medicaid carve-out reconciliation. Monthly reconciliation of Medicaid script claims against 340B fills. Discrepancies are compliance issues.

Revenue at scale

For a mid-size FQHC, the gap between 50% capture and 80% capture is commonly $300K-$1.2M annually. The work to close it is largely operational analytics — there's no clinical change required, just visibility into the eligible-but-uncaptured fills.

The compliance risk angle

340B duplicate-discount findings have led to material recoupments and reputational damage at multiple FQHCs in the past three years. The same analytics layer that recovers leaked revenue also surfaces duplicate-discount risk before it becomes a finding. The two aren't separate projects.

Vizier connects to FQHC EHRs and 340B systems (Sentry / Apexus tools) via direct connector and ships the four views above in a single dashboard. See the FQHC industry page for more.